Scalper1 News
Biotech Alkermes (ALKS) reported Tuesday that its schizophrenia drug hit its goals in a phase-three trial, and it will file for FDA approval next quarter. The stock was up 5% in morning trading on the stock market today, in heavy volume. Alkermes said that after 12 weeks of treatment, its drug aripiprazole lauroxil brought statistically significant improvements in patients’ scores on the Positive and Negative Syndrome Scale, a test measuring a Scalper1 News
Scalper1 News